for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Johnson & Johnson

JNJ.N

Latest Trade

149.17USD

Change

0.97(+0.65%)

Volume

3,395,883

Today's Range

148.00

 - 

149.40

52 Week Range

125.00

 - 

149.40

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
148.20
Open
148.20
Volume
3,395,883
3M AVG Volume
136.46
Today's High
149.40
Today's Low
148.00
52 Week High
149.40
52 Week Low
125.00
Shares Out (MIL)
2,631.87
Market Cap (MIL)
392,596.40
Forward P/E
17.22
Dividend (Yield %)
2.55

Next Event

Q4 2019 Johnson & Johnson Earnings Call

Latest Developments

More

U.S. Court Knocks Down Risperdal Verdict Against J&J's Janssen Unit To $6.8 Million From $8 Billion - Law.Com

Janssen Seeks Expanded Use Of Spravato (Esketamine) Nasal Spray In Europe

Exonate Says To Work With Janssen Research & Development To Develop Eye Drop Treatment For Retinal Vascular Diseases

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being. The Consumer segment includes a range of products used in the baby care, oral care, skin care, over-the-counter pharmaceutical, women's health and wound care markets. The Pharmaceutical segment is focused on five therapeutic areas, including immunology, infectious diseases, neuroscience, oncology, and cardiovascular and metabolic diseases. The Medical Devices segment includes a range of products used in the orthopedic, surgery, cardiovascular, diabetes care and vision care fields. Its research facilities are located in the United States, Belgium, Brazil, Canada, China, France, Germany, India, Israel, Japan, the Netherlands, Singapore, Switzerland and the United Kingdom.

Industry

Biotechnology & Drugs

Contact Info

1 Johnson And Johnson Plz

+1.732.5242455

https://www.jnj.com/

Executive Leadership

Alex Gorsky

Chairman of the Board, Chief Executive Officer

Paulus A. Stoffels

Vice Chairman- Executive Committee, Chief Scientific Officer

Joaquin Boix Duato

Vice Chairman - Executive Committee

Joseph J. Wolk

Chief Financial Officer, Executive Vice President

Peter M. Fasolo

Chief Human Resource Officer, Executive Vice President

Key Stats

2.06 mean rating - 18 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

71.9K

2017

76.5K

2018

81.6K

2019(E)

82.1K
EPS (USD)

2016

6.730

2017

7.300

2018

8.180

2019(E)

8.665
Price To Earnings (TTM)
28.44
Price To Sales (TTM)
4.80
Price To Book (MRQ)
6.74
Price To Cash Flow (TTM)
18.63
Total Debt To Equity (MRQ)
49.34
LT Debt To Equity (MRQ)
46.24
Return on Investment (TTM)
11.38
Return on Equity (TTM)
9.09

Latest News

Latest News

Judge slashes $8 billion Risperdal award against Johnson & Johnson to $6.8 million

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson to a man who said it failed to warn that boys using its antipsychotic drug Risperdal could grow breasts.

Judge slashes $8 bln Risperdal award against Johnson & Johnson to $6.8 mln

A Pennsylvania judge on Friday slashed to $6.8 million from $8 billion a punitive damages award against Johnson & Johnson for allegedly failing to warn men that they could grow breasts by using its antipsychotic drug Risperdal.

China regulator approves imports of J&J's Tremfya

China has approved imports of Johnson & Johnson's Tremfya (guselkumab), the National Medical Products Administration said in a notice on Friday.

J&J to buy remaining stake in Verb Surgical to strengthen digital surgery portfolio

Johnson & Johnson <JNJ.N> said on Friday it would acquire the remaining stake in Verb Surgical Inc, from Verily, Alphabet Inc's <GOOGL.O> life sciences division.

Britain's GSK seeks U.S approval for rival to J&J's multiple myeloma drug

GlaxoSmithKline <GSK.L> said on Monday it had applied for U.S. approval for its experimental multiple myeloma drug that showed meaningful response in nearly a third of patients, setting up a battle against Johnson & Johnson <JNJ.N> and Genmab's Darzalex.

CORRECTED-BRIEF-Hubert Joly Reports Open Market Purchase Of 5,000 Common Shares of J&J At $141.3/Share

* J&J DIRECTOR HUBERT JOLY REPORTS OPEN MARKET PURCHASE OF 5,000 CO'S COMMON SHARES ON DEC 13 AT $141.2798/SHARE - SEC FILING Source (https://bit.ly/2M0tLQc) Further company coverage:

BeiGene cancer drug fails in study against AbbVie: J&J's Imbruvica

BeiGene Ltd said on Monday a late-stage trial failed to show that its cancer treatment Brukinsa was superior to Imbruvica, a rival drug from Johnson & Johnson and AbbVie Inc. The results come merely a month after BeiGene scored a win with Brukinsa's approval to treat patients...

BeiGene drug fails main goal in late-stage study against AbbVie-J&J rival Imbruvica

BeiGene Ltd said on Monday a late-stage trial testing its recently approved cancer treatment Brukinsa did not meet the main goal of proving superior to Imbruvica, a rival medicine from Johnson & Johnson and AbbVie Inc.

J&J CEO spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson <JNJ.N> Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

J&J CEO Gorsky spurns U.S. congressional hearing on carcinogens in talc products

Johnson & Johnson Chief Executive Officer Alex Gorsky has declined to appear at a U.S. congressional hearing set for Tuesday on the safety of the company's Baby Powder and other talc-based cosmetics.

BRIEF-Argenx Receives First Milestone Payment Under Janssen Collaboration

* ARGENX ANNOUNCED ON SATURDAY RECEIPT OF FIRST MILESTONE PAYMENT UNDER JANSSEN COLLABORATION AND PROVIDES DATA UPDATE FROM PHASE 1 DOSE ESCALATION TRIAL OF CUSATUZUMAB IN ACUTE MYELOID LEUKEMIA AT ASH ANNUAL MEETING

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

FDA approves Amgen's biosimilar to J&J's rheumatoid arthritis drug

The U.S. Food and Drug Administration on Friday approved Amgen Inc's biosimilar copy of Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, according to the regulator's website.

Johnson & Johnson says new tests show no asbestos in Johnson's Baby Powder

Johnson & Johnson said on Tuesday that recent tests showed that Johnson's Baby Powder was free of asbestos, after U.S. Food and Drug Administration investigations reported trace amounts of the material in the product earlier this year.

U.S. regions hard hit by opioids to ditch class action, pursue own lawsuits

Local governments in regions hard hit by the U.S. opioid epidemic have opted out of massive litigation taking aim at the drug industry over the crisis, potentially weakening a novel legal mechanism created to help settle thousands of lawsuits.

Johnson & Johnson confirms no asbestos in Johnson's Baby Powder

Johnson & Johnson said on Tuesday that more tests showed that Johnson's Baby Powder was free of asbestos after U.S. Food and Drug Administration investigations had found trace amounts of the material.

Imerys considers sale of North American talc business: Bloomberg

French group Imerys SA <IMTP.PA> is exploring options for its North America talc unit, which filed for bankruptcy after being drawn into cancer lawsuits connected to Johnson & Johnson's <JNJ.N> baby powder, Bloomberg reported on Wednesday, citing people with knowledge of...

Johnson & Johnson loses pelvic mesh class action in Australia

More than 1,350 Australian women won a seven-year-old class action lawsuit on Thursday against Johnson & Johnson (J&J) <JNJ.N> for misleading patients and surgeons about the risks of the pharmaceutical giant's pelvic mesh implants.

Oklahoma judge reduces Johnson & Johnson opioid payout to $465 million

An Oklahoma judge on Friday said Johnson & Johnson must pay that state $465 million for fueling the opioid epidemic through the deceptive marketing of painkillers, down from his original award of $572 million.

Oklahoma judge reduces Johnson & Johnson payout in opioid case to $465 million

An Oklahoma judge on Friday said Johnson & Johnson only needs to pay $465 million of the $572 million he previously concluded it owed the state for fueling the opioid epidemic through deceptive painkiller marketing.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up